Bolt Biotherapeutics (6LP0) Stock Price & Analysis
6LP0 Stock Chart & Stats
- Day’s Range
- EUR 5.18 - EUR 5.78
- 52-Week Range
- EUR 5.18 - EUR 5.78
- Previous Close
- EUR 5.18
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 11.33M
- Enterprise Value
- EUR 10.33M
- Total Cash (Recent Filing)
- EUR 17.60M
- Total Debt (Recent Filing)
- EUR 21.62M
- Price to Earnings (P/E)
- ―
- Beta
- 1.00
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -3.29
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Extended Funding Runway
The financing materially extends Bolt’s ability to operate and advance programs without an immediate funding gap. A runway into 2028 supports multiple clinical and preclinical milestones, gives management more flexibility, and reduces near-term dependence on repeated capital raises.
Expanded Clinical Pipeline
Acquiring a Phase 2 asset and a proprietary antibody platform broadens Bolt beyond its prior oncology focus and creates additional development opportunities. Clinical-stage validation and multiple inflammatory indications could improve pipeline durability if trials produce supportive results.
High Gross Margin
Very high gross profitability indicates that reported revenue carries substantial contribution potential before operating costs. The multi-year reduction in losses and cash burn suggests some progress toward a more efficient model, although the company remains well short of break-even.
Bears Say
Revenue Contraction
Falling revenue on a very small base, combined with a large net loss, shows that Bolt has not yet established a durable commercial earnings stream. Continued operating losses limit internal funding capacity and leave future progress dependent on pipeline execution.
Persistent Cash Burn
Sustained cash outflows make Bolt structurally reliant on equity, debt, or partnership funding to continue operations and clinical development. Even though burn improved from prior years, negative free cash flow remains a material constraint on financial independence.
Elevated Balance-Sheet Risk
Debt exceeding equity reduces financial flexibility while the shrinking asset and equity base provides less support for continued losses. If negative returns persist, leverage can further constrain capital allocation and increase the company’s sensitivity to financing conditions.
Bolt Biotherapeutics News
6LP0 FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
What is Bolt Biotherapeutics’s market cap?
When is Bolt Biotherapeutics’s upcoming earnings report date?
How were Bolt Biotherapeutics’s earnings last quarter?
Is Bolt Biotherapeutics overvalued?
Does Bolt Biotherapeutics pay dividends?
What is Bolt Biotherapeutics’s EPS estimate?
How many shares outstanding does Bolt Biotherapeutics have?
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William Quinn
- Employees
- 23
- Website
- www.boltbio.com
- Address
- 900 Chesapeake Drive, Redwood City, CA, 94063, US
Bolt Biotherapeutics (6LP0) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 5 | 6 |
| Technical Analysis | 2 | 1 | 0 |
| Moving Averages | 2 | 4 | 6 |